First-of-Kind, Dual-CAR T cell Targeting CD19 and CD38 for Comprehensive Elimination of Complex, Multi-System Autoimmune Disorders Advances into ...

Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics to the heart, announced today that the U.S. Food and Drug Administration ...

The planned study will enrol six to eight paediatric and adult patients with PSS in the US and Europe.

Sound Pharmaceuticals is pleased to announce that it completed enrollment of its second Phase 3 open label study of SPI-1005 for the Treatment of Meniere’s Disease (MD). SPI-1005, a novel oral ...

Amicidin-α Surgical Gel is designed to protect the vulnerable tissues of surgical and traumatic wounds and reduce the ...

Apnimed, Inc., a late stage clinical pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep-related ...

Viking Therapeutics recently initiated a Phase 1 single ascending dose trial of VK3019, a dual amylin and calcitonin receptor ...

FDA clearance enables initiation of a planned Phase 1 clinical study evaluating local intravesical administration of UGN-501, with patient ...

Shares of Viking Therapeutics VKTX rose about 9% on Wednesday after the company expanded its obesity pipeline by advancing a ...

The Food and Drug Administration authorized Gain Therapeutics' investigational new drug application for a Parkinson's disease treatment, clearing the way for the biotechnology company to launch a ...

TORONTO, April 01, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a ...

Please provide your email address to receive an email when new articles are posted on . NOV05 will be evaluated in patients with noninfectious anterior uveitis. Novaliq plans to initiate a phase 2 ...